Annual Report And Accounts

Overview

The report describes the company's strong 2020 progress in developing inhaled interferon beta-1a (SNG001), including positive Phase II COVID-19 trial results and initiation of the international Phase III SG018 trial. It also details expansion into home-based and government-funded ACTIV-2 studies. The company raised £101.07 million through two equity issues to fund clinical development, manufacturing and regulatory activities. Manufacturing scale-up and supply-chain preparations progressed through agreements with Akron Biotechnology, Catalent Biologics and Aerogen.

Document

Report type: Annual Report
Class: Financial
Scope: Full report
Fiscal year: 2020
Period: Ends 31 December 2020
Publication date: 11 May 2021
Language: English
Pages
File size

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services